


How to use the BNF



Structure of the BNF

- **Guidance on Prescribing**, (writing a prescription, prescribing in palliative care).
- **Emergency Treatment of Poisoning**, management of acute poisoning.
- **Classified notes on clinical conditions, drugs, and preparations:**
15 chapters, (related to a particular system of the body or to an aspect of medical care). Each chapter is further divided into **classified sections** (usually begins with prescribing notes followed by relevant drug monographs and preparations (see fig. 1)).



Structure of the BNF (cont.)

➤ **Appendices and Indices:** includes **5 Appendices**

1- drug interactions

2- Borderline substances

3- cautionary and advisory labels for dispensed medicines

4- intravenous additives

5- wound management

The Dental Practitioners' Formulary, the Nurse

Prescribers' Formulary, Non medical Prescribing, Index of Manufacturers, and the main Index.







	DRUG NAME 
→	Indications details of clinical uses
→	Cautions details of precautions required and also any monitoring required
→	Counselling Verbal explanation to the patient of specific details of the drug treatment (e.g. posture when taking a medicine)
→	Contra-indications circumstances when a drug should be avoided
→	Hepatic impairment advice on the use of a drug in hepatic impairment
→	Renal impairment advice on the use of a drug in renal impairment
→	Pregnancy advice on the use of a drug during pregnancy
→	Breast-feeding advice on the use of a drug during breast-feeding
→	Side-effects very common (greater than 1 in 10) and common (1 in 100 to 1 in 10); <i>less commonly</i> (1 in 1000 to 1 in 100); <i>rarely</i> (1 in 10 000 to 1 in 1000); <i>very rarely</i> (less than 1 in 10 000); also reported, frequency not known
→	Dose <ul style="list-style-type: none"> • Dose and frequency of administration (max. dose); CHILD and ELDERLY details of dose for specific age group • By alternative route, dose and frequency
	¹ Approved Name (Non-proprietary)  <p>Pharmaceutical form, sugar-free, active ingredient mg/mL, net price, pack size = basic NHS price. Label: (as in Appendix 3)</p> <p>1. Exceptions to the prescribing status are indicated by a note or footnote.</p>
	Proprietary Name (Manufacturer)   <p>Pharmaceutical form, colour, coating, active ingredient and amount in dosage form, net price, pack size = basic NHS price. Label: (as in Appendix 3)</p> <p>Excipients include clinically important excipients</p> <p>Electrolytes clinically significant quantities of electrolytes</p> <p>Note Specific notes about the product e.g. handling</p>

Figure 1

Finding information in the BNF

✓ Index:

where entries are included in alphabetical order of non-proprietary drug names, proprietary drug names, clinical conditions, and prescribing topics. The page reference to the drug monograph is shown in **bold type**.

✓ Contents (p. iv):

provides a hierarchy of how information in the BNF is organised.

✓ The beginning of each chapter:

includes a classified hierarchy of how information is organised in that chapter.



Finding information in the BNF (cont.)

- ✓ **Running heads:**

located next to the page number on the top of each page, show the section of the BNF that is being used.

- ✓ **Thumbnails:**

on the outer edge of each page, show the chapter of the BNF that is being used.

- ✓ **Cross-references:**

lead to additional relevant information in other parts of the BNF.



Index

Principal page references are printed in **bold** type. Proprietary (trade) names and names of organisms are printed in *italic* type; where the BNF does not include a full entry for a branded product, the non-proprietary name is shown in brackets

A

- AZA Spacer*, 192
 Abacavir, 406, **407**, 408
 lamivudine and zidovudine with, 408
 lamivudine with, 408
 Abatacept, 705, **707**
 infusion table, 1026
 Abbreviations
 Latin, *inside back cover*
 prescription writing, 5
 symbols and, *inside back cover*
 Abciximab, 157, **158**, 159
 infusion table, 1026
 Abdominal surgery, antibacterial prophylaxis, 353
 Abelcet, 403
 Abidec, 677
 Abilify preparations, 235
 Abiraterone acetate, **627**
 Able Spacer, 192
 Abortion
 habitual *see* Miscarriage, recurrent, 489
 haemorrhage, 519
 induction, 518
 Abrasive agents, acne, 791
 Abraxane, 599
 Abscess, dental, 349
 Absence seizures, 295
 atypical, 295
 Absopad products, 1037
 Absorbent cotton, bandages, dressings, gauze, 1052, 1054
 Abstral, 279
 Acamprosate, **328**
 Acanthamoeba keratitis, 725, 747
 Acarbose, 460, **463**
 Acaricides, 805
 ACBS
 foods, 973
 toilet preparations, 1007
 Accolate, 200
 Accrete D3, 675
 Accu-Chek products, 470
 Accuhaler
 Flixotide, 197
 Seretide, 198
 Serevent, 187
 ACE inhibitors
 heart failure, 117, 118
 hypertension, 118
 myocardial infarction, 164
 renal function, 118
 Acea, 801
 Acebutolol, **103**
 see also Beta-adrenoceptor blocking drugs
 Aceclofenac, 686, **688**
 Acemetacin, 688
 postoperative pain, 850
 Acenocoumarol, 150, **152**
 Acetaminophen *see* Paracetamol
 Acetazolamide
 diuretic, 93
 epilepsy, 311, **736**
 glaucoma, **736**, 737
 Acetic acid, otitis externa, 749
 Acetylcholine, **742**
 Acetylcysteine
 eye, **739**
 infusion table, 1027
 paracetamol poisoning, 36, **38**
 Acetylsalicylic acid *see* Aspirin
 Aciclovir
 herpes simplex, **418**
 buccal, 759
 eye, 418, 727, **728**
 genital, 418, 804
 labialis, **804**
 skin, **804**
 herpes zoster, **418**
 infusion table, 1027
 varicella-zoster, **418**
 Acid aspiration, 52
 surgery, 842
 Acidex, 47
 Acidosis, metabolic, 652, 655
 Acipimox, **176**
 Acitretin, 781, **784**
 Aclasta, 509
 Aclidinium, **188**
 Acnamino MR, 371
 Acne, **788**
 Acne rosacea *see* Rosacea, 788
 Acnecide, 789
 Acnecin (co-cyprindiol), 792
 Acrivastine, **201**
 Acrolein, 558
 Acromegaly, 499, 511, 629
 ACTH *see* Corticotropin, 495
 Actico, 1059
 Acticoat products, 1048, 1049
 Actidose-Aqua Advance, 35
 Acti-Fast, 1056
 ActiFormCool, 1038
 Aktikerall, 796
 Actilite, 1047
 Actilyse preparations, 165
 Actinic keratosis, 796
 Actisorb Silver, 1049
 ActiV.A.C. products, 1053
 Activated charcoal
 dressings, 1046
 poisoning, use in, 34, **35**
 Active, 470, 471
 ActivHeal products
 alginate, 1045
 foam, 1044
 hydrocolloid, 1042
 hydrogel, 1039
 Activon products, 1047
 Acti-Wrap, 1056
 Actonel preparations, 508
 Actos, 466
 Actrapid preparations, 452
 Acular, 743
 Acumor XL (galantamine), 338
 Acupan, 275
 Acute coronary syndrome, 156, 162
 ACWY Vax, 827
 Acyclovir *see* Aciclovir
 Adalat preparations, 136
 Adalimumab
 Crohn's disease, 61, 62, **67**
 psoriasis, 785, **787**
 rheumatic diseases, 703, **707**
 ulcerative colitis, 61, **67**
 Adapalene, **790**
 benzoyl peroxide with, 790
 Adaptive Touch, 1041
 Adartrel, 318
 Adcal, 665
 Adcal-D₃ preparations, 675
 Adcetris, 578
 Adcirca, 113
 Adcortyl Intra-articular/Intradermal, 697
 Addicts, notification of, 10
 Add-Ins, 1004
 Addiphos, 658
 Addison's disease, 475
 Additives *see* Excipients
 Additrac, 663
 Adefovir, 422, **423**
 Adenocor, 96
 Adenoscan, 96
 Adenosine, **96**
 Adenuric, 714
 Adepend (naltrexone), 337
 ADH *see* Antidiuretic hormone
 ADHD *see* Attention deficit hyperactivity disorder, 257
 Adhesive
 films, 1039
 skin tissue, 807
 Adipine preparations, 136

Contents

Preface	iii
Acknowledgements	v
How the BNF is constructed	ix
How to use the BNF	xi
Changes for this edition	xvii
Significant changes	xvii
Dose changes	xvii
Classification changes	xvii
New names	xvii
Deleted preparations	xviii
New preparations included in this edition	xviii
Guidance on prescribing	1
General guidance	1
Prescription writing	5
Emergency supply of medicines	7
Controlled Drugs and drug dependence	8
Adverse reactions to drugs	12
Prescribing for children	15
Prescribing in hepatic impairment	17
Prescribing in renal impairment	17
Prescribing in pregnancy	19
Prescribing in breast-feeding	19
Prescribing in palliative care	20
Prescribing for the elderly	25
Prescribing in dental practice	27
Drugs and sport	32
Emergency treatment of poisoning	33
Notes on drugs and preparations	44
1: Gastro-intestinal system	44
2: Cardiovascular system	84
3: Respiratory system	178
4: Central nervous system	218
5: Infections	340
6: Endocrine system	448
7: Obstetrics, gynaecology, and urinary-tract disorders	518
8: Malignant disease and immunosuppression	553
9: Nutrition and blood	631
10: Musculoskeletal and joint diseases	685
11: Eye	724
12: Ear, nose, and oropharynx	748
13: Skin	763
14: Immunological products and vaccines	811
15: Anaesthesia	841
Appendices and indices	866
Appendix 1: Interactions	866
Appendix 2: Borderline substances	973
Appendix 3: Cautionary and advisory labels for dispensed medicines	1009
Appendix 4: Intravenous additives	1025
Appendix 5: Wound management products and elasticated garments	1035
Dental Practitioners' Formulary	1062
Nurse Prescribers' Formulary	1064
Non-medical prescribing	1067
Index of manufacturers	1068
Index	1079
Medical emergencies in the community	Inside back cover

2 Cardiovascular system

2 Cardiovascular system

2.1 Positive inotropic drugs	84	2.7.2 Vasoconstrictor sympathomimetics	142
2.1.1 Cardiac glycosides	84	2.7.3 Cardiopulmonary resuscitation	143
2.1.2 Phosphodiesterase type-3 inhibitors	86	2.8 Anticoagulants and protamine	144
2.2 Diuretics	86	2.8.1 Parenteral anticoagulants	144
2.2.1 Thiazides and related diuretics	87	2.8.2 Oral anticoagulants	150
2.2.2 Loop diuretics	89	2.8.3 Protamine sulfate	155
2.2.3 Potassium-sparing diuretics and aldosterone antagonists	90	2.9 Antiplatelet drugs	156
2.2.4 Potassium-sparing diuretics with other diuretics	92	2.10 Stable angina, acute coronary syndromes, and fibrinolysis	162
2.2.5 Osmotic diuretics	93	2.10.1 Management of stable angina and acute coronary syndromes	162
2.2.6 Mercurial diuretics	93	2.10.2 Fibrinolytic drugs	164
2.2.7 Carbonic anhydrase inhibitors	93	2.11 Antifibrinolytic drugs and haemostatics	166
2.2.8 Diuretics with potassium	93	2.12 Lipid-regulating drugs	168
2.3 Anti-arrhythmic drugs	94	2.13 Local sclerosants	177
2.3.1 Management of arrhythmias	94		
2.3.2 Drugs for arrhythmias	95		
2.4 Beta-adrenoceptor blocking drugs	101		
2.5 Hypertension and heart failure	108		
2.5.1 Vasodilator antihypertensive drugs	110		
2.5.2 Centrally acting antihypertensive drugs	113		
2.5.3 Adrenergic neurone blocking drugs	114		
2.5.4 Alpha-adrenoceptor blocking drugs	115		
2.5.5 Drugs affecting the renin-angiotensin system	117		
2.5.5.1 Angiotensin-converting enzyme inhibitors	118		
2.5.5.2 Angiotensin-II receptor antagonists	124		
2.5.5.3 Renin inhibitors	127		
2.6 Nitrates, calcium-channel blockers, and other antianginal drugs	128		
2.6.1 Nitrates	128		
2.6.2 Calcium-channel blockers	131		
2.6.3 Other antianginal drugs	138		
2.6.4 Peripheral vasodilators and related drugs	139		
2.7 Sympathomimetics	141		

This chapter also includes advice on the drug management of the following:

angina, p. 162
 arrhythmias, p. 94
 cardiovascular disease risk, p. 108 and p. 168
 heart failure, p. 117
 hypertension, p. 108
 myocardial infarction, p. 162
 phaeochromocytoma, p. 116
 stroke, p. 157

2.1 Positive inotropic drugs

2.1.1 Cardiac glycosides

2.1.2 Phosphodiesterase type-3 inhibitors

Positive inotropic drugs increase the force of contraction of the myocardium; for sympathomimetics with inotropic activity see section 2.7.1.

2.1.1 Cardiac glycosides

Digoxin is a cardiac glycoside that increases the force of myocardial contraction and reduces conductivity within the atrioventricular (AV) node.

Digoxin is most useful for controlling ventricular response in persistent and permanent atrial fibrillation and atrial flutter (section 2.3.1). For reference to the role of digoxin in heart failure, see section 2.5.5.

For management of atrial fibrillation the maintenance dose of digoxin can usually be determined by the ventri-

12–24 hours after percutaneous coronary intervention); max. duration of treatment 108 hours

- Angiography *within* 4 hours of diagnosis, by **intravenous injection**, 25 micrograms/kg given over 3 minutes at start of percutaneous coronary intervention, then by **intravenous infusion**, 150 nanograms/kg/minute for 18–24 hours; max. duration of treatment 48 hours

Aggrastat® (Corveio) (PvM)

Concentrate for intravenous infusion, tirofiban (as hydrochloride) 250 micrograms/mL. For dilution before use, net price 50-mL (12.5-mg) vial = £146.11

Intravenous infusion, tirofiban (as hydrochloride) 50 micrograms/mL, net price 250-mL *Intravia*® bag = £160.72

2.10 Stable angina, acute coronary syndromes, and fibrinolysis

2.10.1 Management of stable angina and acute coronary syndromes

2.10.2 Fibrinolytic drugs

2.10.1 Management of stable angina and acute coronary syndromes

Stable angina

It is important to distinguish stable angina from unstable angina. *Stable angina* usually results from atherosclerotic plaques in the coronary arteries that restrict blood flow and oxygen supply to the heart; it is often precipitated by exertion and relieved by rest. Treatment involves management of acute anginal pain, and long-term management to prevent angina attacks and to reduce the risk of cardiovascular events.

Management of stable angina

Acute attacks of stable angina should be managed with sublingual **glyceryl trinitrate** (section 2.6.1); sublingual glyceryl trinitrate can also be taken immediately before performing activities that are known to bring on an attack. If attacks occur more than twice a week, regular drug therapy is required and should be introduced in a step-wise manner according to response.

Patients with stable angina should be given a **beta-blocker** (section 2.4) or a **calcium-channel blocker** (section 2.6.2). In those with left-ventricular dysfunction, beta-blocker treatment should be started at a very low dose and titrated very slowly over a period of weeks or months (section 2.5.5); the rate-limiting calcium-channel blockers, diltiazem and verapamil, are contra-indicated in patients with left-ventricular dysfunction because they may precipitate heart failure. If a beta-blocker or a calcium-channel blocker alone fails to control symptoms adequately, a combination of a beta-blocker and a dihydropyridine calcium-channel blocker (e.g. amlodipine, felodipine, modified-release nifedipine) should be used; if this combination is not appropriate due to intolerance of, or contra-indication

to, *either* beta-blockers or calcium-channel blockers, addition of a long-acting **nitrate** (section 2.6.1), **ivabradine**, **nicorandil**, or **ranolazine** (section 2.6.3) can be considered.

For those patients in whom both beta-blockers and calcium-channel blockers are not tolerated or are contra-indicated, monotherapy with a long-acting nitrate, ivabradine, nicorandil, or ranolazine should be considered.

Response to treatment should be assessed every 2–4 weeks after initiating or changing drug therapy; the drug should be titrated (according to symptom control) to the maximum tolerated dose. Consider referring the patient to a specialist if a combination of two drugs fails to control symptoms. Addition of a third antianginal drug should only be considered if symptom control is not achieved with two drugs and the patient is either due to undergo a revascularisation procedure, or a revascularisation procedure is considered inappropriate. See section 2.9 for the use of antiplatelet drugs in patients undergoing coronary stenting.

For long-term prevention of cardiovascular events, see Prevention of cardiovascular events, p. 163.

Acute coronary syndromes

Acute coronary syndromes encompass a spectrum of conditions which include unstable angina, and myocardial infarction with or without ST-segment elevation. Patients with different acute coronary syndromes may present similarly; definitive diagnosis is made on the basis of clinical presentation, ECG changes, and measurement of biochemical cardiac markers.

Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) are related acute coronary syndromes that fall between the classifications of stable angina and ST-segment elevation myocardial infarction (STEMI). They usually occur as a result of atheromatous plaque rupture, and are often characterised by stable angina that suddenly worsens, recurring or prolonged angina at rest, or new onset of severe angina. Patients with unstable angina have no evidence of myocardial necrosis, whereas in NSTEMI, myocardial necrosis (less significant than with STEMI) will be evident. There is a risk of progression to STEMI or sudden death, particularly in patients who experience pain at rest.

ST-segment elevation myocardial infarction (STEMI) is an acute coronary syndrome where atheromatous plaque rupture leads to thrombosis and myocardial ischaemia, with irreversible necrosis of the heart muscle, often leading to long-term complications. STEMI can also occasionally occur as a result of coronary spasm or embolism, arteritis, spontaneous thrombosis, or sudden severe elevation in blood pressure.

Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)

These conditions are managed similarly; the aims of management are to provide supportive care and pain relief during the acute attack and to prevent further cardiac events and death. For advice on the management of patients with acute ST-segment elevation myocardial infarction (STEMI), see below.

12–24 hours after percutaneous coronary intervention); max. duration of treatment 108 hours

- Angiography *within* 4 hours of diagnosis, by **intravenous injection**, 25 micrograms/kg given over 3 minutes at start of percutaneous coronary intervention, then by **intravenous infusion**, 150 nanograms/kg/minute for 18–24 hours; max. duration of treatment 48 hours

Aggrastat® (Corveio) (PoM)

Concentrate for intravenous infusion, tirofiban (as hydrochloride) 250 micrograms/mL. For dilution before use, net price 50-mL (12.5-mg) vial = £146.11

Intravenous infusion, tirofiban (as hydrochloride) 50 micrograms/mL, net price 250-mL *Intravia®* bag = £160.72

2 Cardiovascular system

2.10 Stable angina, acute coronary syndromes, and fibrinolysis

- 2.10.1 Management of stable angina and acute coronary syndromes
- 2.10.2 Fibrinolytic drugs

2.10.1 Management of stable angina and acute coronary syndromes

Stable angina

It is important to distinguish stable angina from unstable angina. *Stable angina* usually results from atherosclerotic plaques in the coronary arteries that restrict blood flow and oxygen supply to the heart; it is often precipitated by exertion and relieved by rest. Treatment involves management of acute anginal pain, and long-term management to prevent angina attacks and to reduce the risk of cardiovascular events.

Management of stable angina

Acute attacks of stable angina should be managed with sublingual **glyceryl trinitrate** (section 2.6.1); sublingual glyceryl trinitrate can also be taken immediately before performing activities that are known to bring on an attack. If attacks occur more than twice a week, regular drug therapy is required and should be introduced in a step-wise manner according to response.

Patients with stable angina should be given a **beta-blocker** (section 2.4) or a **calcium-channel blocker** (section 2.6.2). In those with left-ventricular dysfunction, beta-blocker treatment should be started at a very low dose and titrated very slowly over a period of weeks or months (section 2.5.5); the rate-limiting calcium-channel blockers, diltiazem and verapamil, are contraindicated in patients with left-ventricular dysfunction because they may precipitate heart failure. If a beta-blocker or a calcium-channel blocker alone fails to control symptoms adequately, a combination of a beta-blocker and a dihydropyridine calcium-channel blocker (e.g. amlodipine, felodipine, modified-release nifedipine) should be used; if this combination is not

to, *either* beta-blockers *or* calcium-channel blockers, addition of a long-acting **nitrate** (section 2.6.1), **ivabradine**, **nicorandil**, or **ranolazine** (section 2.6.3) can be considered.

For those patients in whom both beta-blockers *and* calcium-channel blockers are not tolerated or are contra-indicated, monotherapy with a long-acting nitrate, ivabradine, nicorandil, or ranolazine should be considered.

Response to treatment should be assessed every 2–4 weeks after initiating or changing drug therapy; the drug should be titrated (according to symptom control) to the maximum tolerated dose. Consider referring the patient to a specialist if a combination of two drugs fails to control symptoms. Addition of a third antianginal drug should only be considered if symptom control is not achieved with two drugs and the patient is either due to undergo a revascularisation procedure, or a revascularisation procedure is considered inappropriate. See section 2.9 for the use of antiplatelet drugs in patients undergoing coronary stenting.

For long-term prevention of cardiovascular events, see Prevention of cardiovascular events, p. 163.

Acute coronary syndromes

Acute coronary syndromes encompass a spectrum of conditions which include unstable angina, and myocardial infarction with or without ST-segment elevation. Patients with different acute coronary syndromes may present similarly; definitive diagnosis is made on the basis of clinical presentation, ECG changes, and measurement of biochemical cardiac markers.

Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) are related acute coronary syndromes that fall between the classifications of stable angina and ST-segment elevation myocardial infarction (STEMI). They usually occur as a result of atheromatous plaque rupture, and are often characterised by stable angina that suddenly worsens, recurring or prolonged angina at rest, or new onset of severe angina. Patients with unstable angina have no evidence of myocardial necrosis, whereas in NSTEMI, myocardial necrosis (less significant than with STEMI) will be evident. There is a risk of progression to STEMI or sudden death, particularly in patients who experience pain at rest.

ST-segment elevation myocardial infarction (STEMI) is an acute coronary syndrome where atheromatous plaque rupture leads to thrombosis and myocardial ischaemia, with irreversible necrosis of the heart muscle, often leading to long-term complications. STEMI can also occasionally occur as a result of coronary spasm or embolism, arteritis, spontaneous thrombosis, or sudden severe elevation in blood pressure.

Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)

These conditions are managed similarly; the aims of management are to provide supportive care and pain relief during the acute attack and to prevent further cardiac events and death. For advice on the management of patients with acute ST-segment elevation myo-

Prasugrel, in combination with aspirin, is licensed for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (section 2.10.1); the combination is usually given for up to 12 months.

The *Scottish Medicines Consortium* (p. 4) has advised (August 2009) that prasugrel (*Efient*®), in combination with aspirin, be accepted for restricted use within NHS Scotland for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention who are eligible to receive the 10 mg dose of prasugrel.

Antiplatelet drugs and coronary stents Patients selected for percutaneous coronary intervention, with the placement of a coronary stent, will require dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel, or ticagrelor. Aspirin therapy should continue indefinitely. Clopidogrel is recommended for 1 month following elective percutaneous coronary intervention with placement of a bare-metal stent, and for 12 months if percutaneous coronary intervention with placement of a bare-metal stent was for an acute coronary syndrome; clopidogrel should be given for 12 months following placement of a drug-eluting stent. Clopidogrel should not be discontinued prematurely in patients with a drug-eluting stent—there is an increased risk of stent

